Vectorious Medical Technologies today announced interim results from a pilot study of its V-LAP sensor for heart failure management.
Tel Aviv, Israel-based Vectorious presented results from the left atrial pressure (LAP) guided patient self-management study at during an abstract session at THT 2023 in Boston.
The study has 13 enrolled patients to date. It includes New York Heart Association (NYHA) class II and III heart failure (HF) patients. These patients enrolled irrespective of left ventricular ejection fraction and received the V-LAP sensor in the left atrium.
Patients can see direct LAP readings captured by the sensor using a dedicated app and novel treatment paradigm. It allows self-management of diuretics and early intervention in cases of high LAP.
V-LAP allows patients to take a more active role in managing their disease. Using the system, patients can …